Zobrazeno 1 - 10 of 15 pro vyhledávání: '"Lindsay Hladnik"'
1
Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy
Autor: Sean DeFrates, Keith Stockerl-Goldstein, Lindsay Hladnik, Adrienne Nedved
Publikováno v: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 36:1087-1094
Objective Assess the effects of linezolid on hematologic outcomes in newly diagnosed patients with acute myeloid leukemia (AML) following induction chemotherapy. Design Single-center, retrospective, observational, cohort study. Setting Large, tertiar
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f25ffe83d1412b587f07430405d0f7dc
https://doi.org/10.1002/phar.1824
Zobrazit plný text záznamu
4
Use of Cytomegalovirus Intravenous Immune Globulin for the Adjunctive Treatment of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Autor: Erik R. Dubberke, Bryan T. Alexander, Peggy S. McKinnon, Kristan M. Augustin, Ed Casabar, Lindsay Hladnik, Peter Westervelt, Richard M. Reichley, David J. Ritchie
Publikováno v: Pharmacotherapy. 30:554-561
Study Objective. To describe the characteristics and clinical outcomes of hematopoietic stem cell transplant (HSCT) recipients who received adjunctive cytomegalovirus intravenous immune globulin (CMV-IVIG) for probable or proven CMV disease. Design.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14b76a6ff8e6113f662ce36c18cc8180
https://doi.org/10.1592/phco.30.6.554
Zobrazit plný text záznamu
5
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF
Autor: Kristan M. Augustin, Camille N. Abboud, Amanda F. Cashen, Ravi Vij, Keith Stockerl-Goldstein, Ryan Monahan, Sagun D. Goyal, Richard M. Reichley, Lindsay Hladnik, Peter Westervelt, Michael G. Martin, John F. DiPersio, John S. Welch, Divya Tiwari, Geoffrey L. Uy
Publikováno v: American Journal of Hematology. 84:733-737
The current salvage therapies for relapsed/refractory acute myeloid leukemia (AML) are unsatisfactory. Over the past 7 years, we have used two salvage regimens: fludarabine, cytarabine, and idarubicin with (FLAG-IM) or without gemtuzumab ozogamicin (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3ac1b1fc714965ab7e068bafa1cf646
https://doi.org/10.1002/ajh.21545
Zobrazit plný text záznamu
6
Cladribine in the Treatment of Acute Myeloid Leukemia: A Single-Institution Experience
Autor: Kristan M. Augustin, John S. Welch, Lindsay Hladnik, John F. DiPersio, Michael G. Martin, Camille N. Abboud
Publikováno v: Clinical Lymphoma and Myeloma. 9:298-301
Background Despite advances in novel therapeutics, supportive care, and postremission therapy, the outcome of high-risk and elderly patients as well as those with relapsed/refractory acute myeloid leukemia (AML) remains poor. There is likely still ro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ee059be3c3c5b58edf29b7b14903a6d
https://doi.org/10.3816/clm.2009.n.058
Zobrazit plný text záznamu
7
Assessment of an Alternative Meropenem Dosing Strategy Compared with Imipenem-Cilastatin or Traditional Meropenem Dosing After Cefepime Failure or Intolerance in Adults with Neutropenic Fever
Autor: David J. Ritchie, Erik R. Dubberke, Peter Westervelt, Lindsay Hladnik, Kristan M. Augustin, Richard M. Reichley, Peggy S. McKinnon, Heather Arnold, Ed Casabar
Publikováno v: Pharmacotherapy. 29:914-923
Study Objective. To compare clinical outcomes of patients receiving an alternative dosage of meropenem with those of patients receiving imipenem-cilastatin or the traditional dosage of meropenem after failure of or intolerance to cefepime for treatme
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c137afd4b82f91d15413c0d658888e6
https://doi.org/10.1592/phco.29.8.914
Zobrazit plný text záznamu
8
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Autor: Ravi Vij, Kyle McFarland, Keith Stockerl-Goldstein, Camille N. Abboud, Amanda F. Cashen, Lindsay Hladnik, John F. DiPersio, Peter Westervelt, Ibraheem H. Motabi, Geoffrey L. Uy, Kathryn Trinkaus, Shashikant Kulkarni, Michael P. Rettig
Publikováno v: Blood. 119(17)
The interaction of acute myeloid leukemia (AML) blasts with the leukemic microenvironment is postulated to be an important mediator of resistance to chemotherapy and disease relapse. We hypothesized that inhibition of the CXCR4/CXCL12 axis by the sma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ba9ff23a3c76cf1172ee75ca40f0814
https://pubmed.ncbi.nlm.nih.gov/22538491
Zobrazit plný text záznamu
9
Treatment of acute promyelocytic leukemia during pregnancy
Autor: Lindsay Hladnik, Daisy Yang
Publikováno v: Pharmacotherapy. 29(6)
Management of the pregnant patient with acute promyelocytic leukemia (APL) is a challenge. Immediate treatment of APL is critical, as it is an oncologic emergency, with a high risk of morbidity and mortality associated with disseminated intravascular
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::750a7e91901a176c5642aedf4de06ff8
https://pubmed.ncbi.nlm.nih.gov/19476422
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje